What is the main purpose of acquiring PPD, Inc.?

The acquisition aims to enhance Thermo Fisher's services for pharmaceutical and biotechnology customers by integrating PPD's clinical research capabilities, which are expected to accelerate drug development and commercialization.

When was the acquisition of PPD completed?

The acquisition of PPD, Inc. was completed on December 7, 2021, and announced on December 8, 2021.

What impact will this acquisition have on Thermo Fisher's business?

This acquisition is expected to significantly expand Thermo Fisher's reach and capabilities within the life sciences sector, particularly in supporting drug discovery and development pipelines for its clients.

Where can I find more details about this announcement?

More details can be found in the press release issued by Thermo Fisher Scientific on December 8, 2021, which is attached as Exhibit 99.1 to the 8-K filing.

TMO 8-K SEC Disclosure

Summary

Thermo Fisher Scientific Inc. (TMO) announced the successful completion of its acquisition of PPD, Inc. on December 8, 2021. This significant transaction is expected to enhance Thermo Fisher's capabilities in serving pharmaceutical and biotechnology customers. The integration of PPD's clinical research services is anticipated to accelerate drug development and commercialization for their clients, positioning Thermo Fisher for expanded growth in the life sciences sector.

Key Highlights

1Thermo Fisher Scientific has completed the acquisition of PPD, Inc.
2The acquisition is expected to strengthen Thermo Fisher's offerings to pharmaceutical and biotech clients.
3PPD's clinical research services will be integrated into Thermo Fisher's operations.
4The transaction aims to accelerate drug development and commercialization for customers.
5This marks a significant strategic move for Thermo Fisher in the life sciences industry.

THERMO FISHER SCIENTIFIC INC. 8-K Report, Corporate Update (Dec 8, 2021)

Summary

Key Highlights

Frequently Asked Questions